ACTH 1-17 effects in the chemotherapy of advanced solid tumors.
The effect of administration of a synthetic ACTH analogue (ACTH 1-17, Synchrodyn) in the chemotherapy of advanced-phase solid tumors was studied. In this preliminary report the following data are evaluated: response rate; occurrence of toxic effects; performance status of patients; several immunological parameters. The administration of Synchrodyn seems mainly to influence the lymphocyte subpopulations and the occurrence of toxic effects. A final evaluation of the role that may be played by chronotherapy in the treatment of tumors must await further studies on the clinical response and tolerance.
D000324:Adrenocorticotropic Hormone / Q000494:pharmacology / Q000627:therapeutic use*; D002940:Circadian Rhythm / Q000187:drug effects; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D006801:Humans; D007109:Immunity / Q000187:drug effects; D008214:Lymphocytes / Q000187:drug effects; D009369:Neoplasms / Q000188:drug therapy*; D010446:Peptide Fragments / Q000494:pharmacology / Q000627:therapeutic use*
D010446:Peptide Fragments; D000324:Adrenocorticotropic Hormone; C028238:ACTH (1-17)